Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Nanobiotix disclosed that, as of August 31, 2026, it had 50,941,528 shares outstanding, 54,701,246 theoretical voting rights and 54,679,128 exercisable voting rights. The regulatory disclosure contains no operating, clinical-trial, financial-performance or strategic update and is unlikely to affect valuation.

Analysis

This is a statutory capital-and-voting-rights disclosure, not an operating, clinical, financing, or strategic update. It provides no new read-through on Nanobiotix's cash runway, lead-program probability of success, partnering economics, or revenue potential; therefore it should not change fundamental valuation for NBTX. The small gap between theoretical and exercisable votes is consistent with limited treasury shares and does not, by itself, indicate an actionable governance or control event.

Near-term liquidity-sensitive biotech trading can still react if subsequent ownership-threshold filings reveal a concentrated shareholder accumulating or exiting, particularly given the company's dual-listing structure. That would be a flow signal rather than a clinical signal: monitor AMF threshold notices, Nasdaq institutional-position disclosures, average daily value traded, and any ATM/equity issuance authority before attributing price action to fundamentals.

The relevant 1-3 month catalysts remain absent from this release: clinical data timing, regulatory interactions, partner milestones, and quarterly cash-burn guidance. Without a verified change in any of those variables, NBTX should be treated as event-driven clinical-risk exposure rather than a governance trade; NDAQ and ENX have no economically meaningful earnings sensitivity to this disclosure.

Key Decisions for Investors

• No directional trade on NBTX from this filing; maintain existing exposure only against the clinical-calendar and cash-runway thesis, not the reported share/vote count.
• Set an alert for an AMF ownership-threshold filing or a >20% increase in NBTX trading volume sustained for three sessions; investigate whether the move reflects a disclosed holder, financing-related supply, or an undisclosed clinical catalyst before trading.
• For any existing NBTX long, reassess risk if the next earnings release indicates cash runway below 12 months without identified non-dilutive funding or partner payments; that would raise dilution and multiple-compression risk.
• Do not use NDAQ or ENX as sympathy positions: the issuer-level disclosure is immaterial to exchange transaction revenues and listing economics.